Abstract:We have focused our attention on the development of a novel form of a tegafur-based [FT; a prodrug of 5-fluorouracil (5-FU)] antitumor agent. We have used two biochemical and pharmacological modulators of 5-FU to improve its overall activity. To potentiate the antitumor activity of FT, 5-chloro-2,4-dihydroxypyridine (CDHP) was used as a potent reversible inhibitor of 5-FU degradation. The reduction of gastrointestinal (GI) toxicity, induced in the host by 5-FU, was modulated by potassium oxonate (Oxo), an inhibitor of orotate phosphoribosyltransferase that catalyzes the phosphorylation of 5-FU, a process believed to be responsible for the toxic effects of 5-FU. When CDHP and FT were simultaneously given orally to Yoshida sarcoma-bearing rats in various molar ratios, the antitumor effect of FT was significantly potentiated by the combination consisting of at least a 0.2 versus 1 molar ratio of CDHP to FT, respectively. This augmentation of an antitumor activity was supported by potent and prolonged inhibition of dihydrouracil dehydrogenase activity (5-FU degrading activities) in the liver of tumor-bearing rats after oral CDHP (0.2:0.8 molar ratio) and furthermore by elevation and over 12 h retention of 5-FU levels in the tumors following combined administration of FT and CDHP at a molar ratio of 1:0.4, respectively. Moreover, to reduce the severe GI injury and subsequent loss of body weight, observed in parallel with an increased antitumor efficacy, Oxo was given orally to Yoshida sarcoma-bearing rats and nude rats xenografted with H-81 human gastric carcinoma, during consecutive administration of the FT-CDHP mixture. Combined treatment with Oxo and FT (1:2 molar ratio) supplemented with 0.4 molar CDHP resulted in protection of body weight loss without affecting the high antitumor efficacy of the FT-CDHP mixture. When [2-14C]FT plus CDHP was administered with Oxo, the 14C-labeled fluoronucleotide content was objectively decreased in the GI tract of the tumor-bearing rats but not in the tumor and bone marrow, which supports our initial hypothesis. Based on these promising data, we propose a suitable formulation of a FT-based anticancer drug, called S-1, and consisting of FT, CDHP and Oxo at a 1:0.4:1 molar ratio and showing tumor-selective cytotoxicity of 5-FU.

A Novel Brain Targeted 5-Fu Derivative with Potential Antitumor Efficiency and Decreased Acute Toxicity: Synthesis, in Vitro and in Vivo Evaluation.

Synthesis of Novel Spin-Labeled Derivatives of 5-FU As Potential Antineoplastic Agents

The in vitro anti-tumor efficacy and the pharmacokinetics of N 3-O-toluyl-fluorouracil loaded nanosuspension (TFu-LNS)

Synthesis of 5- Fluorouracil Derivative and Its Antitumor Activities in Vitro

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Bio-based Carbon dots Loaded with 5-Fu: A Multifunctional drug Delivery System

Development of 5-Fluorouracil derivatives as anticancer agents.

Synthesis of the Brain-Targeted Prodrug of 5-Fluorouracil Based on Thiamine Disulfide

Functionalized PAMAM-Based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma.

Synthesis and bioevaluation of 5-fluorouracil derivatives.

Multiple-grade prodrugs of 5-flulorouracil:synthesis and anti-tumor activities in mice

Selective Bone Targeting 5-Fluorouracil Prodrugs: Synthesis and Preliminary Biological Evaluation

Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy

Novel Flurbiprofen Derivatives with Improved Brain Delivery: Synthesis, in Vitro and in Vivo Evaluations

Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy

Design, Synthesis, and Evaluation of Doxifluridine Derivatives as Nitroreductase-Responsive Anticancer Prodrugs

Preclinical Studies of N3-O-toluyl-fluorouracil-loaded Lipid-Based Nanosuspensions in H22-bearing Mice

Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents

Activity of Brain Targeted N1-acyl,5-fluorouracil Derivatives to Inhibit the U-251 Astroglioma Across the Blood Brain Barrier in Vitro

An investigation of antitumor efficiency of novel sustained and targeted 5-fluorouracil nanoparticles.

Synthesis and Characterization of New Liver Targeting 5-Fluorouracil-cholic Acid Conjugates